Bogdan Florin Godje

Dr. Bogdan Florin Godje


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
AUAna-Maria Ungureanu
Ana-Maria Ungureanu
BGBogdan Florin Godje
Bogdan Florin Godje
AAAnamaria Alec
Anamaria Alec
DMDaniel Malita
Daniel Malita
SMSergiu-Ciprian Matei
Sergiu-Ciprian Matei
Background: The CT hypoperfusion complex describes a constellation of abdominal vascular, visceral, and parenchymal imaging signs occurring in severe systemic hypotension. Among these findings, pancreatic parenchymal enhancement remains controversial, with both hyperenhancement and hypoenhancement described in the literature. Methods: We performed a retrospective single-center analysis of contrast-enhanced abdominal CT examinations obtained between 1 October 2023 and 31 December 2024 in ICU patients with a clinically established diagnosis of shock. Of 266 patients identified using predefined shock-related ICD-10 codes, 94 underwent abdominal CT, and 44 unique patients fulfilled the imaging criteria for CT hypoperfusion complex, with one examination included per patient. Pancreatic attenuation was assessed across arterial, portal venous, and delayed phases and categorized relative to hepatic and splenic parenchyma as hyperenhancing, hypoenhancing, or isoenhancing. Enhancement categories were correlated with available clinical outcome and laboratory data. Results: The final cohort included 44 unique patients, each contributing one CT examination (mean age 59.5 ± 21.2 years; median 66 years; 28/44 women, 63.6%). Abnormal pancreatic enhancement was observed in 31/44 cases (70.5%): 20/44 (45.5%) showed hyperenhancement or mixed hyperenhancing patterns, 11/44 (25.0%) showed hypoenhancement without hyperenhancement, and 13/44 (29.5%) showed isoenhancement in all evaluable phases. In-hospital outcome data were available for 30/44 patients (68.2%). Among patients with known outcomes, mortality was 20/30 (66.7%). In an exploratory complete-case analysis, mortality was higher in patients with abnormal pancreatic enhancement than in those with isoenhancement (15/18, 83.3%, versus 5/12, 41.7%; Fisher’s exact p = 0.045; OR 7.0, 95% CI 1.29–37.91). The highest observed mortality proportion was found in the hyperenhancement/mixed group (9/10, 90.0%); however, the global comparison across the three pancreatic enhancement categories did not reach statistical significance (Fisher–Freeman–Halton exact p = 0.064). Therefore, this observed high proportion should be interpreted descriptively and does not establish that the hyperenhancement/mixed group had the worst prognosis. In addition, outcome availability differed according to pancreatic enhancement category, and selection bias cannot be excluded. Conclusions: Pancreatic enhancement variability was common among ICU patients with CT hypoperfusion complex. The observed association between abnormal pancreatic enhancement and all-cause in-hospital mortality was derived from an exploratory, unadjusted complete-case analysis and may reflect the severity of the underlying shock. Because outcome data were missing for 31.8% of patients and outcome availability differed according to pancreatic enhancement category, selection bias cannot be excluded. These findings do not establish a causal or independent prognostic role for pancreatic enhancement.

3 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
BGBogdan Florin Godje
Bogdan Florin Godje
SMSergiu-Ciprian Matei
Sergiu-Ciprian Matei
AUAna-Maria Ungureanu
Ana-Maria Ungureanu
DMDaniel Malita
Daniel Malita
OGOvidiu Florin Ghirlea
Ovidiu Florin Ghirlea
MMMarius-Sorin Murariu
Marius-Sorin Murariu
Background and Objectives: Cardiovascular diseases (CVDs) are the leading cause of global morbidity and mortality, and significantly influence perioperative risk in non-cardiac surgery. This study aimed to evaluate the prevalence of cardiovascular comorbidities and their immediate impact on perioperative management in a tertiary surgical center. Materials and Methods: A retrospective cohort study was conducted including all adult patients undergoing elective or emergency non-cardiac surgery between January 2022 and December 2024. Demographic data, primary diagnoses, cardiovascular comorbidities, chronic medication, and perioperative management modifications were analyzed. Descriptive statistical analysis was performed using SPSS v16. Results: A total of 5716 patients were included. Cardiovascular comorbidities were identified in 2157 patients (37.37%). Hypertension (HTN) was the most prevalent condition (33.37%). Surgical delay due to anticoagulation occurred in 4.16% of cases, postponement due to cardiovascular instability in 1.27%, and surgery was contraindicated in 0.50%. Conclusions: Cardiovascular comorbidities are highly prevalent among patients undergoing non-cardiac surgery and frequently require modification of perioperative management strategies. Further studies incorporating postoperative outcomes are needed to better define their impact on surgical prognosis. Structured cardiovascular risk assessment aligned with ESC (European Society of Cardiology) guidelines appears clinically justified, although future outcome-based studies are required.